Stockscreener 앱 받기
4.35
3.82%
0.16
시간 외 거래:
4.39
0.04
+0.92%
Iovance Biotherapeutics Inc 주식(IOVA)의 최신 뉴스
symbol__ Stock Quote Price and Forecast - CNN
IOVAIovance Biotherapeutics Inc Options - Finviz
Heartflow vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
Iovance Biotherapeutics updates corporate presentation, reiterates $350M–$370M FY26 guidance - TradingView
Iovance Biotherapeutics (IOVA) projects 2026 revenue of $350M–$370M and cash runway into 2028 - Stock Titan
IOVA Stock Slump Takes Wall Street, Retail By Surprise — Here’s Why - Stocktwits
IBRX Vs IOVA: Which Cancer Immunotherapy Stock Has Bigger Breakout Ahead? - Stocktwits
IOVA News | IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) - ChartMill
IOVANCE BIOTHERAPEUTICS INC (NASDAQ:IOVA) Passes Mark Minervini’s Trend Template and High-Growth Momentum Screen - ChartMill
Iovance Biotherapeutics Inc Annual Shareholders Meeting Transcript - GuruFocus
REPL Vs IOVA: FDA Decision Day Could Test Biotech Bulls’ Conviction On These Melanoma Plays - Stocktwits
Why Is IOVA Stock Falling Today? - Stocktwits
Enterprise value to revenue forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView
Lost Money on Iovance Biotherapeutics, Inc. (IOVA)? Urged to Join - The National Law Review
Why Iovance Biotherapeutics (IOVA) Is Up 7.7% After Australian Conditional OK For Amtagvi Cell Therapy - Sahm
Iovance Biotherapeutics, Inc. (IOVA) Investigation: Bronstein, Ge - The National Law Review
Investor Alert: Deadline Approaching to Join Iovance Biotherapeut - The National Law Review
IOVA Stockholders Have Opportunity to Lead Iovance Biotherapeutic - The National Law Review
Enterprise value to EBIT forward of Iovance Biotherapeutics Inc – SWB:2LB - TradingView
After IOVA Stock’s Best Day In 2 Years, Analyst Sees Over 300% Upside: Here’s Why - Stocktwits
Price to sales forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Price to sales forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to book forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Price to earnings forward of Iovance Biotherapeutics, Inc. – NASDAQ:IOVA - TradingView
Enterprise value to EBITDA forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to earnings forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
Price to book forward of Iovance Biotherapeutics Inc – LS:A2DT49 - TradingView
IOVA Stock Price, Quote & Chart - ChartMill
Iovance Biotherapeutics Inc Actuals & Estimates (NASDAQ:IOVA) - TradingView
Iovance Biotherapeutics (IOVA) Wins Australia Approval For Amtagvi In Melanoma - Sahm
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - AOL.com
5 Resilient Stocks During Market Bloodbath - Insider Monkey
Iovance (IOVA) Surges 9.4% on Regulatory Nod - Insider Monkey
Amgen vs. Iovance Biotherapeutics: Which Healthcare Stock Is a Better Buy in 2026? - The Motley Fool
Iovance (NASDAQ:IOVA) gains after $89.7 million stock sale - TechStock²
IOVA Stock Climbs As Amtagvi Wins Australia Nod And Pipeline Expands - StocksToTrade
Iovance Biotherapeutics (IOVA) Stock Could Be 53.2% Undervalued After New Shelf Filings - Sahm
Iovance Biotherapeutics grants stock options to 27 new employees under Nasdaq rules. - Pluang
Iovance Biotherapeutics Grants Inducement Stock Options to 27 New Employees - Quiver Quantitative
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
IOVANCE BIOTHERAPEUTICS INC (IOVA) Stock Chart - ChartMill
Iovance Biotherapeutics Inc Files For Mixed Shelf - TradingView
Iovance Biotherapeutics Inc: Sale Agreement P - Moomoo
Director Michael Weiser granted 90,316 deferred RSUs at IOVANCE (NASDAQ: IOVA) - Stock Titan
180,632 deferred stock units granted to Iovance (IOVA) director Dukes - Stock Titan
IOVANCE BIOTHERAPEUTICS (IOVA) director receives 90,316 deferred stock units - Stock Titan
Iovance Biotherapeutics (IOVA) grants 90,316 deferred stock units to director - Stock Titan
IOVANCE (IOVA) awards 15,000 restricted stock units to Chief Regulatory Officer Raj K. Puri - Stock Titan
Iovance Biotherapeutics (NASDAQ: IOVA) files $89.65M at-the-market common stock sale - Stock Titan
Iovance Biotherapeutics Inc (IOVA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Iovance Biotherapeutics Inc (IOVA) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.17%
2.48%
자본화:
|
볼륨(24시간):